A web of EEG electrodes covered Anton Bilton’s scalp like a jeweled headdress, marking the beginning of a scientific experiment designed to push the boundaries of human consciousness. As the potent psychedelic dimethyltryptamine (DMT) entered his bloodstream via a precision intravenous drip, Bilton prepared for an experience that, while familiar through years of personal exploration, promised a level of sustained intensity previously unreachable through traditional methods. This procedure, part of a landmark clinical study at Imperial College London, represents a pivotal shift in psychedelic science: the move from brief, volatile "trips" to the controlled, extended mapping of the DMT realm.
For Bilton, one of 11 volunteers in the 2022 study, the experience was visceral and immediate. He described the moments leading up to the infusion as a period of intense anticipation, likening the wait to having his head in a guillotine. However, once the drug—often referred to as the "spirit molecule"—took hold, the sensation shifted to one of high-velocity transit. Bilton reported arriving in a multidimensional space where he felt scrutinized not only by the medical team in the hospital room but by an array of "alien" entities existing within the psychedelic state itself. Unlike the typical DMT experience, which peaks within minutes and fades shortly thereafter, Bilton’s journey lasted approximately 30 minutes, facilitated by a technological breakthrough known as DMTx.
The Evolution of DMTx: From Anesthesia to Altered States
The concept of "extended DMT" or DMTx was first formalized in a 2016 academic paper co-authored by neurobiologist Andrew Gallimore and psychiatrist Rick Strassman. Strassman, famous for his pioneering DMT research in the 1990s, had long documented the profound, often life-changing encounters reported by participants. Gallimore, a computational neurobiologist, proposed that the state could be stabilized using target-controlled intravenous infusion (TCI).
TCI is a sophisticated technology originally developed for anesthesiology. It utilizes mathematical models to calculate the exact rate of infusion required to maintain a steady concentration of a drug in the patient’s blood and brain. By repurposing this technology for DMT, researchers can bypass the rapid metabolism of the compound by the body, effectively holding the "door" to the psychedelic state open for extended periods. While vaping or smoking DMT typically results in a 10-to-15-minute experience, DMTx allows for sessions lasting 30 minutes, an hour, or potentially longer, providing a stable platform for scientific observation and therapeutic intervention.
The Imperial College London Study and Brain Mapping
The 2022 trial at Imperial College London, led by the Centre for Psychedelic Research, aimed to utilize DMTx to map the neural correlates of the DMT state with unprecedented detail. By using electroencephalography (EEG) and functional magnetic resonance imaging (fMRI), researchers sought to understand how the brain’s connectivity patterns shift when a person "inhabits" the DMT realm.
Preliminary data from such studies suggest that DMT significantly reduces the power of alpha waves—the brain’s dominant rhythm during wakeful relaxation—while simultaneously increasing global connectivity. This "hyper-connected" state is thought to allow different regions of the brain to communicate in ways they usually do not, potentially explaining the vivid hallucinations and profound sense of insight reported by users. The Imperial study was the first to apply these mapping techniques to the extended-infusion model, providing a higher-resolution "snapshot" of the brain under the influence of one of the world’s most powerful psychoactive substances.
Eleusis: A New Model for Research and Wellness in the Caribbean
Building on the foundations laid in London, a new facility named Eleusis is set to launch on March 18 on the island of Bequia, part of St. Vincent and the Grenadines. Named after the ancient Greek site of the Eleusinian Mysteries, the facility aims to bridge the gap between rigorous scientific research and holistic spiritual practice. The project is a collaboration between Noonautics, a nonprofit headed by Andrew Gallimore, and practitioners Charles Patti and Christina Thomas, who operate a ketamine clinic in Florida.
The choice of Bequia is strategic. While DMT remains a Schedule I substance in the United States—classified as having no currently accepted medical use and a high potential for abuse—the regulatory environment in St. Vincent and the Grenadines allows for the legal administration of the drug under the supervision of licensed medical professionals. This legal framework enables Eleusis to offer DMTx sessions to a broader audience than would be possible in most Western nations.
Eleusis is positioned as a "SETI for the mind," a reference to the Search for Extra-Terrestrial Intelligence. Gallimore’s primary interest lies in the phenomenological aspect of the DMT experience: the consistent reports of encounters with seemingly independent, superintelligent entities. By providing a stable, extended environment, Eleusis researchers hope to investigate whether sustained communication with these "entities" is possible and what such interactions might reveal about the nature of consciousness.
Therapeutic Potential and Clinical Applications
Beyond the exploration of "alien" realms, DMTx holds significant promise for clinical medicine. While psilocybin and MDMA have received the most attention in recent years, DMT’s unique pharmacological profile offers distinct advantages. Because the effects can be titrated—meaning the dose can be adjusted up or down in real-time—clinicians have a level of control that is impossible with oral psychedelics. If a patient becomes distressed, the infusion can be slowed or stopped, and the effects will dissipate within minutes.
Current research into DMT is focusing on several key areas:
- Major Depressive Disorder (MDD): Early trials, such as those conducted by Small Pharma (now Cybin), have shown that even short-acting DMT can produce rapid and sustained antidepressant effects.
- Alcohol Use Disorder: Researchers are investigating how the profound perspective shifts induced by DMT can help break the cycle of addiction.
- Neuroplasticity: DMT is known to bind to the Sigma-1 receptor and promote the growth of new neural connections, a process that could be beneficial for treating various neurological conditions.
At Eleusis, the therapeutic side of the operation will be managed by Patti and Thomas, integrating the DMTx sessions with traditional wellness practices such as breathwork and sound healing. This "wrap-around" care is designed to help participants integrate their experiences into their daily lives.
Logistics, Safety, and the Cost of Exploration
The Eleusis experience is designed for a specific demographic, with a four-day introductory package priced at $9,500. This fee includes two DMTx sessions, medical supervision, lodging, and meals. The facility is expected to host its first cohort of 30 guests this month.
Safety remains a paramount concern. All applicants undergo a rigorous screening process to identify contraindications. According to Christina Thomas, individuals with certain cardiovascular conditions, unmanaged psychiatric disorders (such as schizophrenia or bipolar I), or those taking conflicting medications are excluded from participation. The presence of medical experts during the sessions ensures that vital signs are monitored and that the IV administration remains stable throughout the experience.
The Eleusis model is being promoted as a more manageable alternative to ayahuasca. While ayahuasca also contains DMT, it is combined with monoamine oxidase inhibitors (MAOIs) that prolong the effect to several hours. However, ayahuasca is often associated with physical purging (vomiting) and a lack of control over the intensity of the experience. The IV-based DMTx system offers a "cleaner" pharmacological profile and the safety net of an "abort" button, making it more attractive to those who might be wary of the physical rigors of traditional Amazonian ceremonies.
A Timeline of the DMT Renaissance
The path to Eleusis and the Imperial College trials is marked by several key milestones in the history of psychedelic science:
- 1990–1995: Dr. Rick Strassman conducts the first human DMT trials in the U.S. in over 20 years at the University of New Mexico.
- 2016: Andrew Gallimore and Rick Strassman publish "A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Experience" in the journal Frontiers in Psychology.
- 2020–2021: Regulatory shifts and increased funding lead to a surge in psychedelic startups and clinical trials globally.
- 2022: The first clinical DMTx trials are conducted at Imperial College London, proving the feasibility of the extended-infusion model.
- 2024: The launch of Eleusis in Bequia marks the transition of DMTx from a purely experimental research tool to a commercially available therapeutic and exploratory experience.
Broader Implications and Future Directions
The work being done at Imperial College and Eleusis represents a broader trend toward the "medicalization" and "technological enhancement" of the psychedelic experience. As the "Psychedelic Renaissance" continues to gain momentum, the focus is shifting from simply proving that these substances work to optimizing how they are delivered and understood.
Critics of this approach often point to the potential for "commodifying the sacred," arguing that the clinical setting and the high price point of retreats like Eleusis may strip the experience of its traditional and indigenous roots. However, proponents argue that the precision offered by DMTx is essential for bringing these substances into the fold of modern medicine and for conducting the kind of rigorous mapping required to solve the mysteries of the human mind.
The launch of the Bequia facility also raises intriguing questions about the future of "consciousness tourism." If the researchers at Noonautics succeed in establishing what they perceive as "two-way communication" with DMT entities, it could fundamentally alter our understanding of biology, physics, and philosophy. Even if the results remain purely phenomenological, the data gathered from dozens of extended sessions will provide a treasure trove for neuroscientists seeking to decode the brain’s ability to generate complex, immersive realities.
As Anton Bilton’s experience suggests, the frontier of the mind is no longer a place of fleeting glimpses. With the advent of DMTx, humanity is beginning to settle in for a longer stay, armed with the tools of modern science to explore the oldest mysteries of existence. Whether as a tool for healing deep-seated trauma or as a telescope pointed toward internal dimensions, the extended DMT state is poised to become one of the most significant areas of research in the 21st century.
